4-甲基-2-苯基-5-嘧啶甲醛 | 342405-36-1

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-甲基-2-苯基-5-嘧啶甲醛
• 英文名称: 4-methyl-2-phenyl-5-pyrimidinecarboxaldehyde
• 英文别名: 4-methyl-2-phenylpyrimidine-5-carbaldehyde；4-methyl-2-phenyl-5-pyrimidinecarbaldehyde
• CAS: 342405-36-1
• 化学式: C₁₂H₁₀N₂O
• mdl: MFCD02681958
• 分子量: 198.224
• InChiKey: RRWWVHHCAGDAIW-UHFFFAOYSA-N

物化性质

• 沸点：
  258.1±33.0 °C(Predicted)
• 密度：
  1.172±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  4-甲基-2-苯基-5-嘧啶甲醛 、 ethyl 2-(6-fluoro-1-hydroxy-1-indanyl)acetate 在 对甲苯磺酸 、 calcium chloride 、 sodium hydroxide 作用下， 以 甲苯 、 甲醇 为溶剂， 反应 16.0h， 以43 mg的产率得到(E)-2-(5-fluoro-1-((4-methyl-2-phenylpyrimidin-5-yl)methylene)-1H-inden-3-yl)acetic acid
  参考文献：
  名称：

  Cyclooxygenase-1-Selective Inhibitors Based on the (E)-2′-Des-methyl-sulindac Sulfide Scaffold

  摘要：

  Prostaglandins (PGs) are powerful lipid mediators in many physiological and pathophysiological responses. They are produced by oxidation of arachidonic acid (AA) by cyclo- oxygenases (COX-1 and COX-2) followed by metabolism of endoperoidde intermediates by terminal PG synthases. PG biosynthesis is inhibited by nonsteroidal anti-inflammatory drugs (NSAIDs). Specific inhibition of COX-2 has been extensively investigated, but relatively few COX-1-selective inhibitors have been described. Recent reports of a possible contribution of COX-1 in analgesia, neuroinflammation, or carcinogenesis suggest that COX-1 is a potential therapeutic target. We designed, synthesized, and evaluated a series of (E)-2'-des-methyl-sulindac sulfide (E-DMSS) analogues for inhibition of COX-1. Several potent and selective inhibitors were discovered, and the most promising compounds were active against COX-1 in intact ovarian carcinoma cells (OVCAR-3). The compounds inhibited tumor cell proliferation but only at concentrations >100-fold higher than the concentrations that inhibit COX-1 activity. E-DMSS analogues may be useful probes of COX-1 biology in vivo and promising leads for COX-1-targeted therapeutic agents.

  DOI：

  10.1021/jm201528b

文献信息

• [EN] SUBSTITUTED ANILINE DERIVATIVES<br/>[FR] DERIVES D'ANILINE SUBSTITUES
  申请人：LUNDBECK & CO AS H

  公开号：WO2006029623A1

  公开（公告）日：2006-03-23

  The present invention relates to aniline derivatives of the general formula (I) or salts thereof and their use, related to their KCNQ potassium ion channel opening activity.

  本发明涉及一般式(I)的苯胺衍生物或其盐及其用途，与其KCNQ钾离子通道开放活性有关。
• Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
  申请人：sanofi-aventis

  公开号：EP1939180A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及式I的杂环丙烯酰胺， 其中Het、X、Ra、Rb、R1、R2和R3具有权利要求中所示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备式I化合物的方法，包括它们的药物组合物，以及利用式I化合物制造用于刺激内皮型一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
  申请人：sanofi-aventis

  公开号：EP1939181A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的杂环取代羧酰胺，其中Het、A、X、R1、R2和R3具有索引中指示的含义，这些化合物调节内皮一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，公式I的化合物上调内皮一氧化氮合酶酶的表达，并可应用于需要增加该酶的表达或增加NO水平或正常化降低的NO水平的情况。该发明还涉及公式I化合物的制备方法，包括它们的药物组合物，以及公式I化合物用于制造刺激内皮一氧化氮合酶表达或治疗各种疾病的药物的用途，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor)
  申请人：GENESTE Herve

  公开号：US20080300260A1

  公开（公告）日：2008-12-04

  The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.

  本发明涉及异环化合物，这些化合物是代谢型谷氨酸受体的阳性调节剂。本发明还涉及使用这些化合物制备药物组合物以及治疗神经系统和精神疾病的方法，这些疾病与谷氨酸功能障碍有关。
• Substituted aniline derivatives
  申请人：Tornoe Wenzel Christian

  公开号：US20060155121A1

  公开（公告）日：2006-07-13

  The present invention relates to aniline derivatives of the general formula I or salts thereof and their use.

  本发明涉及通式I的苯胺衍生物或其盐以及它们的用途。